Lifecore Biomedical, Inc. De Total Liabilities Growth & History (LFCR)
Lifecore Biomedical, Inc. De's total liabilities was $198.1M for fiscal 2025.
View full Lifecore Biomedical, Inc. De company overviewLifecore Biomedical, Inc. De annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $198.1M | — | — |
| 2025 · May 25 | 2025-05-25 | $191.9M | −$8.1M | −4.07% |
| 2024 | 2024-05-26 | $200.1M | −$18.4M | −8.42% |
| 2023 | 2023-05-28 | $218.5M | $31.6M | +16.90% |
| 2022 | 2022-05-29 | $186.9M | −$113.1M | −37.69% |
| 2021 | 2021-05-30 | $299.9M | −$10.3M | −3.33% |
| 2020 | 2020-05-31 | $310.3M | $61.3M | +24.63% |
| 2019 | 2019-05-26 | $248.9M | $96.8M | +63.63% |
| 2018 | 2018-05-27 | $152.1M | $21.7M | +16.62% |
| 2017 | 2017-05-28 | $130.5M | $153,000 | +0.12% |
| 2016 | 2016-05-29 | $130.3M | $3.9M | +3.12% |
| 2015 | 2015-05-31 | $126.4M | $17.5M | +16.07% |
| 2014 | 2014-05-25 | $108.9M | −$1.7M | −1.51% |
| 2013 | 2013-05-28 | $110.5M | −$15.6M | −12.37% |
| 2012 | 2012-05-27 | $126.1M | $57.5M | +83.91% |
| 2011 | 2011-05-29 | $68.6M | — | — |
Lifecore Biomedical, Inc. De quarterly total liabilities
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $213.4M | — | — |
| Q1 2026 | 2026-03-31 | $204.7M | — | — |
| Q4 2025 · Dec 31 | 2025-12-31 | $198.1M | — | — |
| Q3 2025 · Sep 30 | 2025-09-30 | $198.4M | — | — |
| Q4 2025 · May 25 | 2025-05-25 | $191.9M | −$8.1M | −4.07% |
| Q3 2025 · Feb 23 | 2025-02-23 | $190.3M | $3.5M | +1.85% |
| Q2 2025 | 2024-11-24 | $195.6M | −$7.8M | −3.86% |
| Q1 2025 | 2024-08-25 | $207.3M | −$11.7M | −5.36% |
| Q4 2024 | 2024-05-26 | $200.1M | −$18.4M | −8.42% |
| Q3 2024 | 2024-02-25 | $186.8M | $23.7M | +14.54% |
| Q2 2024 | 2023-11-26 | $203.5M | −$1.4M | −0.66% |
| Q1 2024 | 2023-08-27 | $219.1M | $30.3M | +16.07% |
| Q4 2023 | 2023-05-28 | $218.5M | $31.6M | +16.90% |
| Q3 2023 | 2023-02-26 | $163.1M | −$18.4M | −10.14% |
| Q2 2023 | 2022-11-27 | $204.8M | −$61.1M | −22.97% |
| Q1 2023 | 2022-08-28 | $188.7M | −$63.0M | −25.03% |
| Q4 2022 | 2022-05-29 | $186.9M | −$113.1M | −37.69% |
| Q3 2022 | 2022-02-27 | $181.5M | −$123.7M | −40.53% |
| Q2 2022 | 2021-11-28 | $265.9M | −$24.3M | −8.37% |
| Q1 2022 | 2021-08-29 | $251.8M | −$33.3M | −11.67% |
| Q4 2021 | 2021-05-30 | $299.9M | −$10.3M | −3.33% |
| Q3 2021 | 2021-02-28 | $305.2M | $2.8M | +0.93% |
| Q2 2021 | 2020-11-29 | $290.2M | −$10.7M | −3.56% |
| Q1 2021 | 2020-08-30 | $285.0M | $3.8M | +1.36% |
| Q4 2020 | 2020-05-31 | $310.3M | $61.3M | +24.63% |
| Q3 2020 | 2020-02-23 | $302.4M | $70.9M | +30.61% |
| Q2 2020 | 2019-11-24 | $300.9M | $142.8M | +90.36% |
| Q1 2020 | 2019-08-25 | $281.2M | $131.7M | +88.06% |
| Q4 2019 | 2019-05-26 | $248.9M | $96.8M | +63.63% |
| Q3 2019 | 2019-02-24 | $231.5M | $95.8M | +70.63% |
| Q2 2019 | 2018-11-25 | $158.1M | $11.5M | +7.83% |
| Q1 2019 | 2018-08-26 | $149.5M | $13.7M | +10.10% |
| Q4 2018 | 2018-05-27 | $152.1M | $21.7M | +16.62% |
| Q3 2018 | 2018-02-25 | $135.7M | $13.7M | +11.22% |
| Q2 2018 | 2017-11-26 | $146.6M | $24.8M | +20.37% |
| Q1 2018 | 2017-08-27 | $135.8M | $9.0M | +7.08% |
| Q4 2017 | 2017-05-28 | $130.5M | $153,000 | +0.12% |
| Q3 2017 | 2017-02-26 | $122.0M | −$75,000 | −0.06% |
| Q2 2017 | 2016-11-27 | $121.8M | −$12.6M | −9.40% |
| Q1 2017 | 2016-08-28 | $126.8M | $8.2M | +6.95% |
| Q4 2016 | 2016-05-29 | $130.3M | $3.9M | +3.12% |
| Q3 2016 | 2016-02-28 | $122.1M | −$2.7M | −2.19% |
| Q2 2016 | 2015-11-29 | $134.4M | $4.4M | +3.42% |
| Q1 2016 | 2015-08-30 | $118.6M | $168,000 | +0.14% |
| Q4 2015 | 2015-05-31 | $126.4M | $17.5M | +16.07% |
| Q3 2015 | 2015-03-01 | $124.8M | $17.7M | +16.48% |
| Q2 2015 | 2014-11-30 | $130.0M | $18.0M | +16.07% |
| Q1 2015 | 2014-08-31 | $118.4M | $13.0M | +12.38% |
| Q4 2014 | 2014-05-25 | $108.9M | — | — |
| Q3 2014 | 2014-02-23 | $107.1M | −$1.2M | −1.08% |
| Q2 2014 | 2013-11-24 | $112.0M | $1.6M | +1.48% |
| Q1 2014 | 2013-08-25 | $105.4M | — | — |
| Q4 2013 | 2013-05-28 | $110.5M | −$15.6M | −12.37% |
| As of May 26, 2013 | 2013-05-26 | $110.5M | −$15.6M | −12.37% |
| Q3 2013 | 2013-02-24 | $108.3M | $46.4M | +74.88% |
| Q2 2013 | 2012-11-25 | $110.4M | $43.4M | +64.73% |
| Q4 2012 | 2012-05-27 | $126.1M | $57.5M | +83.91% |
| Q3 2012 | 2012-02-26 | $61.9M | — | — |
| Q2 2012 | 2011-11-27 | $67.0M | — | — |
| Q1 2012 | 2011-08-28 | $67.5M | — | — |
| Q4 2011 | 2011-05-29 | $68.6M | — | — |
Lifecore Biomedical, Inc. De total liabilities trends
Between the periods ended 2011-05-29 and 2025-12-31, Lifecore Biomedical, Inc. De's total liabilities increased from $68.6M to $198.1M, a change of $129.5M. The latest reported quarter, Q2 2026, shows $213.4M.
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lifecore Biomedical, Inc. De source filings ↗